ReviewAnnals of the rheumatic diseases2005
Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
Review in Annals of the rheumatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 60 citations in OpenAlex.
- Melatonin, an Antitumor Necrosis Factor Therapy.Journal of pineal research · 2025Review
- Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.Pediatric nephrology (Berlin, Germany) · 2018Review
- Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Review
- Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis.CNS drugs · 2016Article
- Biologics for the treatment of autoimmune renal diseases.Nature reviews. Nephrology · 2016Review
- Wegener's disease presenting with occipital condyle syndrome.Frontiers in neurology · 2012Article
- Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab.Clinical rheumatology · 2010Article
- Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis.Journal of clinical immunology · 2009Article
- Wegener's granulomatosis: the current view.Clinical reviews in allergy & immunology · 2008Review
- [Diagnosis, therapy and current research aspects of selected chronic inflammatory diseases with head and neck involvement].Zeitschrift fur Rheumatologie · 2008Review
- Small-vessel vasculitis: therapeutic management.Current rheumatology reports · 2007Review
- The safety of etanercept for the treatment of plaque psoriasis.Therapeutics and clinical risk management · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour necrosis factor alpha (TNFalpha) is likely to be involved in the pathogenesis of Wegener's granulomatosis. This paper reviews published clinical trials of the anti-TNFalpha agents etanercept and infliximab with regard to their efficacy and safety in the treatment of Wegener's granulomatosis. On the basis of the high rate of adverse events, particularly an increased incidence of cancers, the use of etanercept in the management of Wegener's granulomatosis is not justified. However, the potential role for infliximab or the as yet untested adalimumab cannot be discounted. The development of novel approaches focusing on blockade of specific molecules including TNFalpha in the treatment of Wegener's granulomatosis is awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.